Therapeutic Asset Ratings

188 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
egf816 Neuroblastoma	Cancer Research UK	P2/3	CC (47)
egf816 Soft Tissue Sarcoma	Cancer Research UK	P2/3	CC (47)
egf816 Solid Tumour	Cancer Research UK	P2/3	CC (47)
htl0039732 capsules Esophageal Cancer	Cancer Research UK	P1/2	CC (47)
htl0039732 capsules Kidney Neoplasm	Cancer Research UK	P1/2	CC (47)
ucb4594 Advanced Solid Tumours	Cancer Research UK	P1/2	CC (47)
ucb4594 Esophageal Cancer	Cancer Research UK	P1/2	CC (47)
ucb4594 Triple-Negative Breast Carcinoma	Cancer Research UK	P1/2	CC (47)
egf816 Cancer	Cancer Research UK	P2/3	CC (46)
egf816 Glioma	Cancer Research UK	P2/3	CC (46)
Aleta-001 Diffuse Large B-Cell Lymphoma	Cancer Research UK	P1/2	CC (45)
Atezolizumab Malignant Mesothelioma	Cancer Research UK	P1/2	CC (45)
Atezolizumab Gastric Neoplasm	Cancer Research UK	P1/2	CC (45)
Atezolizumab Uterine Cervix Neoplasm	Cancer Research UK	P1/2	CC (45)
Capmatinib Gastric Cancer	Cancer Research UK	P2/3	CC (45)
Gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV4-3101 (89.9%) -(IGHD) -IGHJ401 (92.9%), CDR-IMGT [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo sapiens IGHG101 (100%), G1m17,1 CH1 K120, D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-1201 (85.3%)-IGKJ201 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1,glycoform alfa Castration-Resistant Prostate Carcinoma	Cancer Research UK	P1/2	CC (45)
htl0039732 capsules Head And Neck Neoplasm	Cancer Research UK	P1/2	CC (45)
htl0039732 capsules Malignant Mesothelioma	Cancer Research UK	P1/2	CC (45)
htl0039732 capsules Pancreatic Neoplasm	Cancer Research UK	P1/2	CC (45)
htl0039732 capsules Castration-Resistant Prostate Carcinoma	Cancer Research UK	P1/2	CC (45)
htl0039732 capsules Gastric Neoplasm	Cancer Research UK	P1/2	CC (45)
htl0039732 capsules Uterine Cervix Neoplasm	Cancer Research UK	P1/2	CC (45)
ucb4594 Pancreatic Neoplasm	Cancer Research UK	P1/2	CC (45)
ucb4594 Head And Neck Squamous Cell Carcinoma	Cancer Research UK	P1/2	CC (45)
ucb4594 Uterine Cervix Neoplasm	Cancer Research UK	P1/2	CC (45)

Showing 126 to 150 of 188 assets

PreviousPage 6 of 8Next